Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a...

Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be showcased in seven presentations and...

OnQuality Pharmaceuticals ("OnQuality"), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving...

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...